Accord Healthcare, Ltd. (Accord) and HIPRA, today announced that they have entered into an exclusive distribution agreement to commercialise HIPRA’s COVID-19 vaccine in the United Kingdom (UK). The vaccine was fully developed in the European Union (EU) and consists of a bivalent adjuvanted vaccine containing a recombinant protein.

HIPRA’s COVID vaccine, Bimervax, was authorised by the UK MHRA on July 31st, 2023, as a booster for active immunisation to prevent COVID-19 in individuals 16 years of age and older who have previously received a mRNA COVID-19 vaccine. The main trial compared the immune response triggered by HIPRA’s vaccine with that triggered by the Comirnaty mRNA vaccine (Pfizer/BioNTech).

Following the results, the UK MHRA and EMA concluded that the benefits of HIPRA’s vaccine outweigh its risks and recommended the granting of the marketing authorisation in the UK and the EU zone countries, respectively.

“We are delighted to collaborate with HIPRA to make available a recombinant protein based COVID-19 vaccine in the United Kingdom, this provides an additional option to help to combat what is still a health threat.” said Paul Tredwell, Executive Vice President of Accord Healthcare Ltd.

“We are proud to partner with Accord to commercialise BIMERVAX in UK. The HIPRA COVID-19 vaccine is the first human health vaccine to be designed, developed and fully manufactured in Spain. Having the structures and capabilities ranging from the most basic research and development to the production of vaccines in the country is a key factor in being able to support a rapid response in the event of future health emergencies and reinforces the strategic autonomy of Europe in the field of health.” said Carles Fàbrega, Managing Director of HIPRA Human Health.